

RESEARCH

Open Access



Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer's dementia

Lisa Y. Xiong^{1,2}, Michael Ouk¹, Che-Yuan Wu^{1,2}, Jennifer S. Rabin^{1,3,4,5}, Krista L. Lanctôt^{1,2,6,7}, Nathan Herrmann^{1,6}, Sandra E. Black^{1,7,8}, Jodi D. Edwards^{9,10,11} and Walter Swardfager^{1,2,7,8*} 

Abstract

Background: Leukotriene receptor antagonists (LTRAs) alleviate Alzheimer's disease (AD) pathology and improve cognition in animal models; however, clinical evidence is limited. This study aimed to explore the associations between the use of LTRAs (montelukast or zafirlukast) and cognitive performance in people with normal cognition, mild cognitive impairment (MCI), or AD dementia. We hypothesized that LTRA use would be associated with better cognitive performance over time.

Methods: This longitudinal observational study used data from the National Alzheimer's Coordinating Center. Within groups of participants with normal cognition, MCI, or AD dementia, LTRA users were matched 1:3 to non-users using propensity score matching. Cognitive domains including immediate and delayed memory (Wechsler Memory Scale Revised-Logical Memory IA and IIA), psychomotor processing speed (Digit Symbol Substitution Test), and language (animal naming, vegetable naming, and Boston Naming Test) were compared between users and non-users in mixed-effects linear or Poisson regression models.

Results: In AD dementia, LTRA use was associated with a slower decline in psychomotor processing speed, as measured by the Digit Symbol Substitution Test ($B = 1.466$ [0.253, 2.678] symbols/year, $n = 442$), and language, as measured by animal naming ($B = 0.541$ [0.215, 0.866] animals/year, $n = 566$), vegetable naming ($B = 0.309$ [0.056, 0.561] vegetables/year, $n = 565$), and the Boston Naming Test ($B = 0.529$ [0.005, 1.053] items/year, $n = 561$). Effect sizes were small but persisted after controlling for a 10% false discovery rate. LTRA use was not associated with changes in memory performance in AD, nor was it associated with changes in cognitive performance in people with normal cognition or MCI. In a post hoc analysis, LTRA use was associated with a slower decline in clinical progression in MCI ($B = -0.200$ [-0.380, -0.019] points/year, $n = 800$) and AD dementia ($B = -0.321$ [-0.597, -0.046] points/year, $n = 604$) as measured by CDR Sum of Boxes.

* Correspondence: w.swardfager@utoronto.ca

¹Dr. Sandra Black Centre for Brain Resilience & Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada

²Department of Pharmacology & Toxicology, University of Toronto, Room 4207, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Conclusions: The use of LTRAs was associated with preserved function in non-amnestic cognitive domains in AD dementia. The role of leukotrienes and their receptors in cognitive decline warrants further investigation and the leukotriene pathway may represent a target for AD treatment.

Keywords: Alzheimer's disease, Mild cognitive impairment, Leukotriene receptor antagonists, Cognition, Language, Memory, Psychomotor processing, Clinical function

Background

Current treatments for Alzheimer's disease (AD) are limited, and there is a need to explore potential mechanisms that might result in new treatment options. The leukotriene pathway is an inflammatory signaling pathway that has been implicated in multiple brain disorders including cerebral ischemia [1], dementia with Lewy bodies [2], and AD. In AD, proinflammatory responses mediated by leukotrienes have been suggested to modulate amyloid beta formation [3] and tau hyperphosphorylation [4]; therefore, repurposing leukotriene receptor antagonists (LTRAs) for AD is being explored [5–8].

LTRAs including montelukast and zafirlukast are indicated for asthma maintenance and allergic rhinitis. LTRAs exert their effects by inhibiting the binding of cysteinyl leukotrienes to their receptors, cysteinyl leukotriene receptor 1 (CysLTR1), and G-coupled protein receptor 17 (GPR17), thereby preventing proinflammatory signaling by the cysteinyl leukotrienes [9, 10]. It has been suggested that the pathophysiology of asthma and AD may be linked through activation of eicosanoid pathways which increase leukotriene production [11].

Preclinical animal studies suggest that administration of LTRAs may ameliorate AD-related pathology and associated cognitive decline [6–8]; however, human studies have been limited to three reports. One study on a large cohort of healthy people aged ≥ 60 years in Norway found that compared to use of inhaled corticosteroids, use of the LTRA montelukast was associated with a lower risk of dementia as indicated by the use of dementia medication (memantine, donepezil, rivastigmine, or galantamine). That study also found a lower risk of entering long-term care among people aged ≤ 75 [12]. A second study, also conducted in Norway, reported that compared to non-users, the use of montelukast was cross-sectionally associated with numerically but not significantly better performance in global cognition, psychomotor processing speed, and immediate free recall among a small sample (< 150) of older people [13]. Those results were among the first to suggest clinical benefits associated with the use of LTRAs, but the study may have been underpowered. In a case series of 17 dementia patients given montelukast, patients or their caregivers reported subjective improvements in memory and agitation [14]. Although these studies suggest possible benefits of LTRA use, there have been no

longitudinal studies on LTRA use and objective cognitive performance, and no studies on LTRA use specifically among people with pre-existing mild cognitive impairment (MCI) or AD dementia.

The aim of this longitudinal study was to compare cognitive performance over time between users and non-users of an LTRA in a relatively larger sample of people with normal cognition, MCI, or AD dementia. We hypothesized that the use of an LTRA would be associated with a slower decline in cognitive performance over time.

Methods

Data source

The National Alzheimer's Coordinating Center (NACC) has Alzheimer's Disease Research Centers (ADRCs) located across the USA funded by the National Institute on Aging. The NACC maintains the Uniform Data Set (UDS) which is comprised of prospective, standardized, and longitudinal clinical data as previously described [15, 16]. Since its inception, there have been three versions of the UDS. Participants are recruited to the ADRCs through clinician referral, self-referral, or are recruited by community organizations. Data are collected approximately annually by trained clinicians and clinic personnel from participants and their co-participants (usually a close friend or family member) using a standardized evaluation via in-person office visits, home visits, and telephone calls.

Participant selection

Data used in this analysis were collected between September 2005 and February 2021 from 42 ADRCs. Clinical diagnoses of cognitive status were made at each UDS visit by a single physician or consensus team. Participants were classified as cognitively normal if they had normal cognition and did not use any dementia-related medications (memantine, donepezil, rivastigmine, galantamine, or tacrine) at baseline. Participants were classified as MCI upon first diagnosis of MCI. Participants were classified as AD upon first diagnosis of all-cause dementia with AD being identified as a primary or contributing cause of cognitive impairment, as defined by NINCDS-ADRDA or NIA-AA criteria [17, 18]. Only participants who completed the medication form and

had baseline data for the identified matching factors were included.

All-cause dementia was diagnosed using established criteria as previously described [17–19]. MCI was diagnosed using the Petersen's criteria [20]. Normal cognition was defined as not exhibiting any dementia-related symptoms and having a global score of 0 from the CDR® Dementia Staging Instrument or neuropsychological testing within the normal range.

Drug exposure

Medication use at each visit was identified by trained clinicians or ADRC staff using a structured medication inventory. Participants or co-participants were asked to bring or report all medications that were used within 2 weeks prior to each study visit. Participants who had used an LTRA (montelukast or zafirlukast) were included. LTRA users at baseline were compared to those who were never exposed to an LTRA.

The use of other classes of respiratory medications were also identified, including other medications for asthma maintenance, chronic obstructive pulmonary disease (COPD), allergies, or use of a rescue inhaler for asthma; these additional medications were included as covariates in the analysis. As measures of respiratory disease severity (e.g., spirometry) were not available in the database, these respiratory medications were used as a proxy for respiratory disease severity.

Cognitive outcomes

The outcomes of interest were immediate and delayed logical memory, psychomotor processing speed, and language and were selected based on the findings from a previous study on montelukast and neurological function and the domains most affected by AD dementia [13, 21]. Immediate and delayed logical memory were assessed using the Wechsler Memory Scale Revised-Logical Memory Test IA (total number of story units recalled immediately) and IIA (total number of story units recalled after a 20-min delay) [22]. Psychomotor processing speed was measured by the Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol Substitution Test (number of correct symbols) [23]. Language was assessed using Animal naming (total number of animals named in 60 s), vegetable naming (total number of vegetables named in 60 s) [24], and the Boston Naming Test (total items named correctly) [25]. In all tests, a higher score indicates better performance.

Between versions 2 and 3 of the UDS, there was a change in the neuropsychological test battery, resulting in the replacement of some cognitive tests. New test scores in version 3 were converted to their equivalent scores on previous tests with the results from the Crosswalk Study [26] (i.e., Craft Immediate and Delayed Recall

to Logical Memory Test IA and IIA and Multilingual Naming Test to Boston Naming Test).

Statistical analysis

Analyses were conducted using R 4.0.5 [27] and figures were created using the ggplot2 package [28].

Propensity score matching (MatchIt package [29]) was performed to minimize confounding by indication and to create a group of non-users that was comparable to LTRA users in clinically important factors. Users were matched to non-users using the greedy nearest neighbor matching method in a 1:3 ratio. Matched groups were created for each of the normal cognition, MCI, and AD groups.

Propensity scores were calculated using age, sex, education, body mass index (BMI), smoking history (reported total years smoked > 0), use of other respiratory medications, apolipoprotein E (*APOE*) ϵ 4 carrier status, use of dementia medications, CDR global score [30], and evidence of vascular contribution to dementia. Vascular contribution to dementia was defined by NINDS-AIREN criteria [31] or neurological evidence of cerebrovascular disease, cortical cognitive deficit (e.g., aphasia, apraxia, neglect), or subcortical ischemic vascular dementia as previously defined [32].

The associations between LTRA use and performance on immediate and delayed logical memory over time were assessed using mixed-effects Poisson regression models with random slopes (glmmTMB package [33]) as immediate and delayed logical memory are count variables following Poisson-like distributions. Effect sizes were reported as rate ratios (RRs), which indicate the fold-change in score over time. The associations between LTRA use and performance on the Digit Symbol Substitution Test, animal naming, vegetable naming, and Boston Naming Test were assessed using mixed-effects linear regression models with random slopes (lme4 package [34]). The mixed-effects models were able to handle missing follow-up data. Effect sizes were reported as unstandardized (B) and standardized (β) regression coefficients. Analyses were performed separately for the normal cognition, MCI, and AD groups. To reduce potential residual confounding, the use of dementia medication at each visit and matching factors with standardized mean difference (SMD) ≥ 0.1 between users and non-users in the matched groups was included as covariates in the outcome models. Within each group, results were controlled for multiple comparisons using the Benjamini-Hochberg method [35] with a 10% false discovery rate (FDR).

Previous studies on the benefits of LTRAs in AD dementia have only included users of montelukast [12, 13]. To ensure that our results were comparable to those studies and not influenced by the inclusion of zafirlukast,

a post hoc analysis was performed excluding the zafirlukast users by matching users of montelukast to non-users of an LTRA. To compare clinical progression in users and non-users of LTRAs, a separate post hoc analysis was performed in the MCI and AD groups with CDR Sum of Boxes (CDR-SOB) as an outcome.

Results

Participant characteristics

Of 43,746 participants, 11,976 participants met the criteria for inclusion into the normal cognition group, 7782 met the criteria for inclusion into the MCI group, and 8918 met the criteria for inclusion into the AD group. After conducting propensity score matching, the matched samples for normal cognition, MCI, and AD contained 1,400, 800, and 604 participants, respectively (participant selection flowchart shown in Figure S1). Baseline characteristics of each group after propensity score matching are presented in Table 1. The majority of LTRA users (99.8%) were using montelukast, and the remaining were using zafirlukast.

In the normal cognition sample, LTRA users ($n = 350$, median follow-up = 4.08 [1.79, 7.08] years, 86.3% with ≥ 2 observations) and non-users ($n = 1050$, median follow-up = 3.98 [1.59, 7.21] years, 85.9% with ≥ 2 observations) were balanced in clinical characteristics that were identified to be of importance except for small imbalances in the use of a rescue inhaler for asthma (SMD = 0.162) and use of a maintenance inhaler for asthma (SMD = 0.115), which were used by a greater proportion of LTRA users. These variables were included as covariates in the outcome model to account for possible residual confounding. The median follow-up time and proportion of participants with ≥ 2 observations did not differ significantly between users and non-users.

In the MCI sample, LTRA users ($n = 200$, median follow-up = 2.11 [0.96, 4.69] years, 77.5% with ≥ 2 observations) and non-users ($n = 600$, median follow-up = 2.46 [1.04, 4.91] years, 82.5% with ≥ 2 observations) were balanced in all identified clinical factors. The median follow-up time and proportion of participants with ≥ 2 observations did not differ significantly between users and non-users.

In the AD sample, LTRA users ($n = 151$, median follow-up = 1.92 [0.00, 3.84] years, 74.2% with ≥ 2 observations) and non-users ($n = 453$, median follow-up = 1.94 [0.00, 3.84] years, 72.0% with ≥ 2 observations) were balanced in all identified clinical factors except for a small imbalance in baseline CDR global score (SMD = 0.119), where a greater proportion of users had higher CDR global scores than non-users (i.e., had greater dementia severity). Baseline CDR global score was included as a covariate in the outcome model. The median follow-up time and proportion of participants with ≥ 2

observations did not differ significantly between users and non-users.

Relationship between LTRA use and cognition in the matched sample with normal cognition

In the normal cognition sample, LTRA use was associated with a 0.8% faster rate of decline over time in immediate memory (RR = 0.992 [0.985, 0.998]) which remained statistically significant after controlling for FDR. No other differences in performance over time were observed between LTRA users and non-users (Table 2).

Relationship between LTRA use and cognition in the matched sample with MCI

In the MCI sample, LTRA use was associated with a slower decline in psychomotor processing speed as measured by the Digit Symbol Substitution Test ($B = 0.690$ [0.035, 1.344] symbols/year); however, this finding did not remain significant after FDR correction. No other differences in performance over time were observed between LTRA users and non-users (Table 3).

Relationship between LTRA use and cognition in the matched sample with AD dementia

In the AD sample, LTRA use was associated with a slower decline in performance on tests of psychomotor processing speed and language (Table 4). Specifically, LTRA users showed better performance over time on the Digit Symbol Substitution Test ($B = 1.466$ [0.253, 2.678] symbols/year; Fig. 1), Boston Naming Test ($B = 0.529$ [0.005, 1.053] items/year; Fig. 2A), animal naming ($B = 0.541$ [0.215, 0.866] animals/year; Fig. 2B), and vegetable naming ($B = 0.309$ [0.056, 0.561] vegetables/year; Fig. 2C). These results remained significant after FDR correction. Effect sizes were relatively small (Table 4). LTRA use was not associated with a change in immediate (RR = 1.048 [0.972, 1.130]; Figure S2A) or delayed memory (RR = 1.065 [0.932, 1.217]; Figure S2B) performance.

All results were consistent in a post hoc analysis excluding the zafirlukast users by matching users of montelukast to non-users of an LTRA (Tables S4, S5, and S6). In another post hoc analysis using CDR-SOB, the use of LTRAs was associated with a slower decline in clinical progression in the participants with AD dementia ($B = -0.321$ [-0.597, -0.046] points/year) and MCI ($B = -0.200$ [-0.380, -0.019] points/year) (Table S7).

In each analysis, a small number of participants who were included in the matching procedure did not provide cognitive data; however, inclusion of factors with SMD ≥ 0.1 as covariates in the outcome models for each comparison did not change the results.

Table 1 Baseline participant characteristics by LTRA use in normal, MCI, and AD groups following propensity score matching

	Normal			MCI			AD		
	User	Non-user	SMD	User	Non-user	SMD	User	Non-user	SMD
	(n = 350)	(n = 1050)		(n = 200)	(n = 600)		(n = 151)	(n = 453)	
Baseline demographics									
Age (years)	70.30 (9.71)	70.37 (9.56)	0.007	73.75 (8.86)	73.94 (8.76)	0.021	75.35 (9.73)	75.24 (10.13)	0.011
Female	261 (74.6%)	793 (75.5%)	0.022	110 (55.0%)	321 (53.5%)	0.030	93 (61.6%)	265 (58.5%)	0.063
BMI (kg/m ²)	29.41 (6.21)	29.70 (6.78)	0.045	27.82 (5.54)	27.92 (6.17)	0.018	27.03 (6.05)	26.93 (5.08)	0.018
Education (years)	15.77 (3.29)	15.81 (2.82)	0.013	15.23 (3.32)	15.15 (3.27)	0.024	13.87 (4.51)	14.03 (3.77)	0.038
Smoking history (total years smoked > 0)	158 (45.1%)	471 (44.9%)	0.006	86 (43.0%)	273 (45.5%)	0.050	60 (39.7%)	199 (43.9%)	0.085
Dementia measures									
CDR global score			0.019			0.065			0.119
0	316 (90.3%)	942 (89.7%)		25 (12.5%)	72 (12.0%)		0 (0.0%)	0 (0.0%)	
0.5	34 (9.7%)	108 (10.3%)		172 (86.0%)	523 (87.2%)		58 (38.4%)	200 (44.2%)	
1	0 (0.0%)	0 (0.0%)		3 (1.5%)	5 (0.8%)		61 (40.4%)	168 (37.1%)	
2	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)		28 (18.5%)	73 (16.1%)	
3	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)		4 (2.6%)	12 (2.6%)	
APOE ε4 carrier	116 (33.1%)	347 (33.0%)	0.002	84 (42.0%)	247 (41.2%)	0.017	81 (53.6%)	252 (55.6%)	0.040
Vascular dementia	0 (0.0%)	0 (0.0%)	< 0.001	7 (3.5%)	29 (4.8%)	0.067	6 (4.0%)	14 (3.1%)	0.048
AD medication use	0 (0.0%)	0 (0.0%)	< 0.001	52 (26.0%)	155 (25.8%)	0.004	100 (66.2%)	302 (66.7%)	0.009
Other respiratory medication use									
Allergy medications	152 (43.4%)	477 (45.4%)	0.040	82 (41.0%)	240 (40.0%)	0.020	51 (33.8%)	163 (36.0%)	0.046
COPD medications	27 (7.7%)	58 (5.5%)	0.088	27 (13.5%)	65 (10.8%)	0.082	17 (11.3%)	48 (10.6%)	0.021
Rescue inhaler for asthma	82 (23.4%)	178 (17.0%)	0.162	40 (20.0%)	129 (21.5%)	0.037	36 (23.8%)	92 (20.3%)	0.085
Maintenance inhaler for asthma	136 (38.9%)	350 (33.3%)	0.115	78 (39.0%)	211 (35.2%)	0.079	49 (32.5%)	140 (30.9%)	0.033

Continuous variables expressed as mean (standardized deviation); categorical variables expressed as counts (proportion)
 Abbreviations: AD Alzheimer's disease, BMI body mass index, COPD chronic obstructive pulmonary disease, MCI mild cognitive impairment, and SMD standardized mean difference

Table 2 Associations between LTRA use and cognitive test performance over time in the normal cognition group

	<i>n</i>		RR or B [95% CI]	β [95% CI]	<i>z</i> or <i>t</i>	<i>p</i> value
	User	Non-user				
Logical memory						
Immediate memory	345	1040	RR = 0.992 [0.985, 0.998]	-	-2.55	.0106*
Delayed memory	345	1040	RR = 0.995 [0.987, 1.002]	-	-1.24	.2134
Psychomotor processing speed						
Digit Symbol Substitution Test	278	742	<i>B</i> = 0.158 [-0.099, 0.414]	0.012 [-0.007, 0.031]	1.21	.2284
Language						
Boston Naming Test	344	1041	<i>B</i> = -0.020 [-0.081, 0.041]	-0.007 [-0.026, 0.013]	-0.65	.5134
Animal naming	345	1043	<i>B</i> = 0.046 [-0.056, 0.148]	0.008 [-0.011, 0.026]	0.88	.3773
Vegetable naming	345	1039	<i>B</i> = -0.017 [-0.093, 0.062]	-0.004 [-0.021, 0.014]	-0.40	.6912

Abbreviations: RR rate ratio, B unstandardized coefficient, z for logical memory, and t for all other tests
Significant at FDR 0.1

Discussion

In people with AD dementia, LTRA use was associated with better performance over time on tests for psychomotor processing speed and language but not memory. These longitudinal associations support the hypothesis that LTRAs may warrant investigation as a potential target for AD treatment. The lack of association with cognition among people with normal cognition and MCI does not provide evidence to support a role of LTRAs in slowing cognitive decline among people with normal cognition or MCI, although a small but significant effect on clinical progression was seen in both AD dementia and MCI groups.

The finding that LTRA use was associated with better performance in specific cognitive domains over time in AD dementia extends the results of a previous cross-sectional study, which found that the use of montelukast was associated with positive but non-significant differences in cognitive performance in people with undefined cognitive status [13]. That previous study suggested that

the use of LTRAs may benefit cognition in older people, but it may have been underpowered due to sample sizes < 150 participants. The NACC data provided a larger sample of LTRA users than had been previously available, longitudinal assessments, data to characterize participants with respect to their cognitive status, and allowed us to carefully match users to non-users. By stratifying participants based on cognitive status, we show that associations between LTRA use and cognition over time were largest in people with pre-existing AD dementia. A positive association between LTRA use and performance on the Digit Symbol Substitution Test was also observed in people with MCI. Although the finding did not survive FDR correction, it is noteworthy that the effect size was smaller in MCI compared to AD, and absent in people with normal cognition. A previous cohort study found that the use of montelukast was associated with a lower risk of using a dementia medication and entering a nursing home [12], which may be consistent with our finding that LTRAs were associated with less

Table 3 Associations between LTRA use and cognitive test performance over time in the MCI group

	<i>n</i>		RR or B [95% CI]	β [95% CI]	<i>z</i> or <i>t</i>	<i>p</i> value
	User	Non-user				
Logical memory						
Immediate memory	197	582	RR = 1.015 [0.991, 1.039]	-	1.24	.2150
Delayed memory	197	581	RR = 1.032 [0.993, 1.074]	-	1.59	.1120
Psychomotor processing speed						
Digit Symbol Substitution Test	150	431	<i>B</i> = 0.690 [0.035, 1.344]	0.055 [0.003, 0.107]	2.07	.0400
Language						
Boston Naming Test	197	584	<i>B</i> = 0.189 [-0.049, 0.427]	0.035 [-0.009, 0.079]	1.55	.1210
Animal naming	197	584	<i>B</i> = 0.189 [-0.043, 0.421]	0.034 [-0.008, 0.075]	1.59	.1120
Vegetable naming	197	581	<i>B</i> = 0.035 [-0.129, 0.200]	0.001 [-0.030, 0.047]	0.42	.6755

RR rate ratio, B unstandardized coefficient, z for logical memory, and t for all other tests


*Significant at FDR 0.1

Table 4 Associations between LTRA use and cognitive test performance over time in the AD dementia group

	<i>n</i>		RR or <i>B</i> [95% CI]	β [95% CI]	<i>z</i> or <i>t</i>	<i>p</i> value
	User	Non-user				
Logical memory						
Immediate memory	141	419	RR = 1.048 [0.972, 1.130]	-	1.22	.2230
Delayed memory	140	416	RR = 1.065 [0.932, 1.217]	-	0.93	.3550
Psychomotor processing speed						
Digit Symbol Substitution Test	112	330	<i>B</i> = 1.466 [0.253, 2.678]	0.100 [0.017, 0.182]	2.37	.0192*
Language						
Boston Naming Test	141	420	<i>B</i> = 0.529 [0.005, 1.053]	0.069 [0.001, 0.137]	1.98	.0492*
Animal naming	143	423	<i>B</i> = 0.541 [0.215, 0.866]	0.101 [0.040, 0.162]	3.26	.0014*
Vegetable naming	143	422	<i>B</i> = 0.309 [0.056, 0.561]	0.079 [0.015, 0.143]	2.40	.0176*

RR rate ratio, *B* unstandardized coefficient, *z* for logical memory, and *t* for all other tests


*Significant at FDR 0.1



cognitive decline and slower clinical progression in dementia, although the link would require further study. The results also suggest that the protective effects of LTRAs on cognition shown in some preclinical literature may be relevant in humans; for instance, montelukast improved cognition in a mouse model of AD [7] and in aged rats [6].

The use of LTRAs was not associated with better cognitive performance over time in people with normal cognition. In this group, the use of LTRAs was associated with a faster decline in immediate memory; however, the difference between users and non-users was < 1% and unlikely to be of clinical importance. Because users of an LTRA were matched for the use of other respiratory medications for allergy, COPD and asthma, they were using an additional medication, which may indicate a greater burden of allergic airway disease in the group of LTRA users. The approach was conservative and intended to avoid the overestimation of possible LTRA benefits; however, it is possible that the LTRA users could have had higher disease burden, which could also account for the small difference between groups seen in immediate memory performance.

Among people with AD dementia, the use of an LTRA was associated with better performance on tests of language and psychomotor processing speed. Although the use of LTRAs was positively associated with performance on tests for immediate and delayed memory in people with AD dementia, these associations were small and non-significant. The domains in which significant effects were found agree with the cross-sectional study described previously, which reported positive but non-significant associations with psychomotor processing speed and immediate free recall among older people using montelukast [13]. No studies thus far had examined language or delayed memory specifically. The results contrast a preclinical study, which showed that the administration of montelukast improved memory in



aged rats [6]. A second study using the 5xFAD mouse model found that montelukast did not improve memory outcomes but improved learning outcomes [7], suggesting possible benefits of LTRAs on some cognitive domains. Although there may be interspecies differences, the present findings suggest that the preclinical findings may be relevant in humans and that the associations with LTRAs were larger for language and processing speed than for memory.

Given the different findings between AD dementia, cognitively normal or MCI groups, it might be speculated that the mechanisms underlying the benefits of LTRAs are more relevant later in the course of AD progression. In rodent models, administration of montelukast enhanced neurogenesis, increased blood-brain barrier (BBB) integrity, and reduced neuroinflammation [6, 7, 36], which may be of benefit in the context of accumulated AD pathology. Although montelukast may penetrate the BBB [37], it is unclear if it enters the brain at concentrations sufficient to have effects in the central nervous system in humans at the doses currently used in asthma treatment. At these concentrations, LTRAs may be acting primarily on the vasculature which may explain the beneficial effects observed in vascular-related cognitive

domains such as psychomotor processing speed but not necessarily domains most specific to AD such as memory. Poor BBB penetration could also explain the relatively small effect sizes observed and effects seen only in AD where BBB disruption may be more appreciable. The observed effect sizes on cognition were small, which may indicate that the use of current LTRAs may have limited clinical utility; however, a post hoc analysis showed an effect on CDR-SOB in MCI and AD, suggesting that the use of LTRAs may have slowed dementia progression more broadly. Taken together, the results show that the leukotriene pathway warrants further investigation in AD treatment, either with currently available LTRAs (e.g., larger dose, increased frequency, or different route of administration) or with new investigational drugs that are targeting this pathway. Recently, a buccal film was produced which may help increase bioavailability of montelukast and achieve higher plasma concentrations [37]. Further studies are needed, particularly clinical trials, to determine potential efficacy and dose-response relationships between the LTRA use and cognition.

Cysteinyl leukotrienes are lipid mediators derived from arachidonic acid that activate CysLTR1 and GPR17 [9, 10]. They elicit a wide range of pro-inflammatory effects, including the expression of adhesion molecules and

recruitment and activation of leukocytes [38, 39]. In addition to binding leukotriene receptors, LTRAs may have off-target effects; for instance, both montelukast and zafirlukast may inhibit soluble epoxide hydrolase (sEH) and modulate peroxisome proliferator activated receptor γ (PPAR γ) at therapeutically relevant plasma concentrations [40]. These activities may be of benefit in AD; for instance, sEH inhibitors ameliorated AD pathology and improved behavior in the 5xFAD mouse model [41], and PPAR γ agonists reduced cortical and hippocampal amyloid beta levels and improved spatial memory performance in the APP/PS1 mouse model [42]. Circulating metabolites of sEH were associated with cerebral small vessel disease and with poorer performance in associated cognitive domains [43, 44], offering one possible explanation for the preservation of psychomotor processing speed seen here. Further studies would be needed to elucidate the potential mechanisms of LTRAs in humans.

Limitations

This study has important limitations. Although LTRA users were well matched to non-users on important demographics and use of other respiratory medications to minimize potential confounding by indication, clinician diagnoses related to the indication (e.g., asthma) were not available, and effects of unmeasured confounders (e.g., lung function) cannot be ruled out. Since patients were matched for other respiratory medications, LTRA users were using an LTRA in addition to those medications, and they may have had more severe respiratory disease overall; however, these differences may have biased the results towards the null, suggesting that the effect sizes may have been conservative in their estimates. Although LTRAs included montelukast and zafirlukast, only seven participants (0.2%) used zafirlukast. A sensitivity analysis which included only montelukast users did not change the results, but more data would be required to generalize the conclusions to zafirlukast users. Our analyses could not account for adherence, frequency of usage, duration of usage, or dosage of medications since these data were not collected in the UDS. Higher doses of montelukast resulted in better learning performance in 5xFAD mice, suggesting that a dose-response relationship may exist [7]. Future studies should examine possible dose effects and compare short- vs. long-term LTRA use. Although the use of prescribed allergy medications (decongestants, antihistamines, and nasal corticosteroids) was matched for, the use of over-the-counter medications was not collected systematically, and therefore, some exposures to allergy medications may not have been accounted for. Drug exposures before entering NACC were not recorded, and

observations where medication data was not provided were excluded from the analyses, which could have contributed to misclassification of the exposure group. Although MRI data were available in NACC, they were not available in a sufficient number of participants to explore the associations between the LTRA use and imaging measures. AD was identified using clinical criteria due to insufficient biomarker or post-mortem data in the NACC to confirm diagnoses. Future studies might examine biomarker confirmed subgroups and also the effects of LTRA use on biomarker progression and imaging measures. Participants were recruited by many ADRC sites, but they may not be representative of the general population in certain factors such as educational attainment, socioeconomic status, and proportions of Whites and women, which could reduce generalizability.

Conclusion

The use of LTRAs was associated with slower decline in specific domains of cognitive performance and slower clinical decline in AD dementia. These results provide clinical evidence suggesting that the leukotriene pathway may be relevant in the progression of AD and that there may be potential benefits of treatments that target the pathway.

Abbreviations

AD: Alzheimer's disease; ADRC: Alzheimer's Disease Research Centers; APOE: Apolipoprotein E; BBB: Blood-brain barrier; COPD: Chronic obstructive pulmonary disease; CysLTR1: Cysteinyl leukotriene receptor 1; FDR: False discovery rate; GPR17: G-coupled protein receptor 17; LTRA: Leukotriene receptor antagonist; MCI: Mild cognitive impairment; NACC: National Alzheimer's Coordinating Center; PPAR γ : Peroxisome proliferator activated receptor γ ; RR: Rate ratio; sEH: Soluble epoxide hydrolase; SMD: Standardized mean difference; UDS: Uniform Data Set

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13195-021-00892-7>.

Additional file 1. Participant selection flow chart, figure showing logical memory performance over time in the AD dementia group, table of respiratory medications, table of participant characteristics before propensity score matching, and tables for post-hoc analyses.

Acknowledgements

The NACC database is funded by the NIA/NIH Grant U01 AG016976 and AG032984. NACC data are contributed by the NIA-funded ADRCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI Robert Vassar, PhD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG005131 (PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez,

MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), and P50 AG047270 (PI Stephen Strittmatter, MD, PhD).

Authors' contributions

LYX, MO, CW, JDE, and WS designed the study. LYX, MO, and CW acquired and analyzed the data. LYX and WS interpreted the data and drafted the manuscript. MO and CW provided edits on the manuscript. JSR, KLL, NH, SEB, and JDE provided expert feedback on the study and edits on the manuscript. WS provided overall supervision to the study. The authors have read and approved the final manuscript.

Funding

This work was funded by the Canadian Institutes of Health Research (PJT-159711), Natural Sciences and Engineering Research Council of Canada (RGPI N-2017-06962), Alzheimer's Association & Brain Canada (AARG501466), Weston Brain Institute, Alzheimer's Research UK, Alzheimer's Association, and Michael J. Fox Foundation (BAND3). The funders were not involved at any stage of the study.

Availability of data and materials

The data analyzed in the current study are available through the NACC, <https://naccdata.org/>.

Declarations

Ethics approval and consent to participate

As determined by the University of Washington Human Subjects Division, the NACC database itself is exempt from IRB review and approval because it does not involve human subjects, as defined by federal and state regulations. However, all contributing ADRCs are required to obtain informed consent from their participants and to maintain their own separate IRB review and approval from their institution prior to submitting data to NACC. Written informed consent was obtained from all participants and co-participants at the ADRCs.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Dr. Sandra Black Centre for Brain Resilience & Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada. ²Department of Pharmacology & Toxicology, University of Toronto, Room 4207, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada. ³Harquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada. ⁴Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. ⁵Rehabilitation Sciences Institute, University of Toronto, Toronto, Canada. ⁶Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. ⁷KITE UHN Toronto Rehabilitation Institute, Toronto, Canada. ⁸Canadian Partnership for Stroke Recovery, Toronto, Canada. ⁹University of Ottawa Heart Institute, University of Ottawa, Ottawa, Canada. ¹⁰School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada. ¹¹ICES, Ottawa, Canada.

Received: 7 June 2021 Accepted: 24 August 2021

Published online: 03 September 2021

References

- Zhang X-Y, Wang X-R, Xu D-M, Yu S-Y, Shi Q-J, Zhang L-H, et al. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. *J Pharmacol Exp Ther*. 2013;346(2):328–41 Available from: <https://doi.org/10.1124/jpet.113.203604>.
- Marschallinger J, Altendorfer B, Rockenstein E, Holztrattner M, Garnweidner-Raith J, Pillichshammer N, et al. The leukotriene receptor antagonist montelukast reduces alpha-synuclein load and restores memory in an animal model of dementia with Lewy bodies. *Neurotherapeutics*. 2020;17:1061–74 Available from: <https://doi.org/10.1007/s13311-020-00836-3>.
- Chu J, Praticò D. 5-lipoxygenase as an endogenous modulator of amyloid beta formation in vivo. *Ann Neurol*. 2011;69(1):34–46 Available from: <https://doi.org/10.1002/ana.22234>.
- Vagnozzi AN, Giannopoulos PF, Praticò D. The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy. *Transl Psychiatry*. 2017;7(12):1288 Available from: <https://doi.org/10.1038/s41398-017-0017-2>.
- Lai J, Mei ZL, Wang H, Hu M, Long Y, Miao MX, et al. Montelukast rescues primary neurons against Ab1–42-induced toxicity through inhibiting CysLT1R-mediated NF- κ B signaling. *Neurochem Int*. 2014;75:26–31 Available from: <https://doi.org/10.1016/j.neuint.2014.05.006>.
- Marschallinger J, Schäffner I, Klein B, Gelfert R, Rivera FJ, Illes S, et al. Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. *Nat Commun*. 2015;6(8466):1–16 Available from: <https://doi.org/10.1038/ncomms9466>.
- Michael J, Zirknitzer J, Unger MS, Poupardin R, Rieß T, Paiement N, et al. The leukotriene receptor antagonist montelukast attenuates neuroinflammation and affects cognition in transgenic 5xFAD mice. *Int J Mol Sci*. 2021;22(5):2782 Available from: <https://doi.org/10.3390/ijms22052782>.
- Lai J, Hu M, Wang H, Hu M, Long Y, Miao M, et al. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates A β 1–42-induced memory impairment and neuroinflammatory and apoptotic responses in mice. *Neuropharmacology*. 2014;79:707–14 Available from: <https://doi.org/10.1016/j.neuropharm.2014.01.011>.
- Lipworth BJ. Leukotriene-receptor antagonists. *Lancet*. 1999;353(9146):57–62 Available from: [https://doi.org/10.1016/S0140-6736\(98\)09019-9](https://doi.org/10.1016/S0140-6736(98)09019-9).
- Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. *EMBO J*. 2006;25(19):4615–27 Available from: <https://doi.org/10.1038/sj.emboj.7601341>.
- Wang S, Li B, Solomon V, Fonteh A, Rapoport SI, Bennett DA, et al. Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4. *Mol Neurodegener*. 2021;16(26):1–18 Available from: <https://doi.org/10.1186/s13024-021-00438-3>.
- Grinde B, Engdahl B. Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified. *Immun Ageing*. 2017;14(20):1–7 Available from: <https://doi.org/10.1186/s12979-017-0102-7>.
- Grinde B, Schirmer H, Eggen AE, Aigner L, Engdahl B. A possible effect of montelukast on neurological aging examined by the use of register data. *Int J Clin Pharm*. 2021;43:541–548. Available from: <https://doi.org/10.1007/s11096-020-01160-8>.
- Rozin SI. Case series using montelukast in patients with memory loss and dementia. *Open Neurol J*. 2017;11:7–10 Available from: <https://doi.org/10.2174/1874205X01711010007>.
- Morris JC, Weintraub S, Chui HC, Cummings J, DeCarli C, Ferris S, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. *Alzheimer Dis Assoc Disord*. 2006;20(4):210–6 Available from: <https://doi.org/10.1097/01.wad.0000213865.09806.92>.
- Besser L, Kukull W, Knopman DS, Chui H, Galasko D, Weintraub S, et al. Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. *Alzheimer Dis Assoc Disord*. 2018;32(4):351–8 Available from: <https://doi.org/10.1097/WAD.0000000000000279>.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984;34(7):939–44 Available from: <https://doi.org/10.1212/wnl.34.7.939>.
- McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):263–9 Available from: <https://doi.org/10.1016/j.jalz.2011.03.005>.
- American Psychiatric Association. *Diagnostic and statistical manual of mental disorders: DSM-IV*. 4th ed. Washington, DC: American Psychiatric Association; 1994.
- Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med*. 2004;256(3):183–94 Available from: <https://doi.org/10.1111/j.1365-2796.2004.01388.x>.

21. Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. *Cold Spring Harb Perspect Med*. 2012;2(4):a006171 Available from: <https://doi.org/10.1101/cshperspect.a006171>.
22. Wechsler D. WMS-R: Wechsler Memory Scale-Revised Manual. San Antonio: Psychological Corporation; 1987.
23. Wechsler D. WAIS-R Manual: Wechsler Adult Intelligence Scale-Revised. New York: Harcourt Brace Jovanovich [for] Psychological Corp; 1981.
24. Isaacs B, Kennie AT. The set test as an aid to the detection of dementia in old people. *Br J Psychiatry*. 1973;123(575):467–70 Available from: <https://doi.org/10.1192/bjp.123.4.467>.
25. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia: Lea & Febiger; 1983.
26. Monsell SE, Dodge HH, Zhou X-H, Bu Y, Besser LM, Mock C, et al. Results from the NACC Uniform Data Set neuropsychological battery crosswalk study. *Alzheimer Dis Assoc Disord*. 2016;30(2):134–9 Available from: <https://doi.org/10.1097/WAD.0000000000000111>.
27. R Core Team. R: a language and environment for statistical computing [Internet]. Vienna: R Foundation for Statistical Computing; 2021. Available from: <https://www.R-project.org/>
28. Wickham H. ggplot2: elegant graphics for data analysis [Internet]. New York: Springer-Verlag; 2016. Available from: <https://ggplot2.tidyverse.org>
29. Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. *J Stat Softw*. 2011;42(8):1–28 Available from: <https://doi.org/10.18637/jss.v042.i08>.
30. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993;43(11):2412–4 Available from: <https://doi.org/10.1212/WNL.43.11.2412>.
31. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Amaducci L, et al. Vascular dementia: diagnostic criteria for research studies. *Neurology*. 1993;43(2):250–60 Available from: <https://doi.org/10.1212/wnl.43.2.250>.
32. Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. *Lancet Neurol*. 2002;1(7):426–36 Available from: [https://doi.org/10.1016/S1474-4422\(02\)00190-4](https://doi.org/10.1016/S1474-4422(02)00190-4).
33. Brooks ME, Kristensen K, van Benthem KJ, Magnusson A, Berg CW, Nielsen A, et al. glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. *R J*. 2017;9(2):378–400 Available from: <https://doi.org/10.32614/RJ-2017-066>.
34. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Softw*. 2015;67(1):1–48 Available from: <https://doi.org/10.18637/jss.v067.i01>.
35. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Ser B Methodol*. 1995;57(1):289–300 Available from: <https://doi.org/10.1111/j.2517-6161.1995.tb02031.x>.
36. Zhou L, Sun X, Shi Y, Liu J, Luan G, Yang Y. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood–brain barrier. *Inflammopharmacology*. 2019;27(5):933–40 Available from: <https://doi.org/10.1007/s10787-019-00611-7>.
37. Michael J, de Sousa DB, Conway J, Gonzalez-Labrada E, Obeid R, Tevini J, et al. Improved bioavailability of montelukast through a novel oral mucoadhesive film in humans and mice. *Pharmaceutics*. 2020;13(12):1–17 Available from: <https://doi.org/10.3390/pharmaceutics13010012>.
38. Woszczek G, Chen L-Y, Nagineni S, Kern S, Barb J, Munson PJ, et al. Leukotriene D4 induces gene expression in human monocytes through cysteinyl leukotriene type 1 receptor. *J Allergy Clin Immunol*. 2008;121(1):215–221.e1 Available from: <https://doi.org/10.1016/j.jaci.2007.09.013>.
39. Fregonese L, Silvestri M, Sabatini F, Rossi GA. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT₁ receptor-mediated mechanism: cysteinyl leukotriene activity. *Clin Exp Allergy*. 2002;32(5):745–50 Available from: <https://doi.org/10.1046/j.1365-2222.2002.01384.x>.
40. Göbel T, Diehl O, Heering J, Merk D, Angioni C, Wittmann SK, et al. Zafirlukast is a dual modulator of human soluble epoxide hydrolase and peroxisome proliferator-activated receptor γ . *Front Pharmacol*. 2019;10:263 Available from: <https://doi.org/10.3389/fphar.2019.00263>.
41. Ghosh A, Comerota MM, Wan D, Chen F, Propson NE, Hwang SH, et al. An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease. *Sci Transl Med*. 2020;12(573):eabb1206 Available from: <https://doi.org/10.1126/scitranslmed.abb1206>.
42. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPAR γ /RXR α -induced and CD36-mediated microglial amyloid- β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. *J Neurosci*. 2012;32(48):17321–31 Available from: <https://doi.org/10.1523/JNEUROSCI.1569-12.2012>.
43. Yu D, Hennebelle M, Sahlas DJ, Ramirez J, Gao F, Masellis M, et al. Soluble epoxide hydrolase-derived linoleic acid oxylipins in serum are associated with periventricular white matter hyperintensities and vascular cognitive impairment. *Transl Stroke Res*. 2019;10(5):522–33 Available from: <https://doi.org/10.1007/s12975-018-0672-5>.
44. Shinto L, Lahna D, Murchison CF, Dodge H, Hagen K, David J, et al. Oxidized products of omega-6 and omega-3 long chain fatty acids are associated with increased white matter hyperintensity and poorer executive function performance in a cohort of cognitively normal hypertensive older adults. *J Alzheimers Dis*. 2020;74(1):65–77 Available from: <https://doi.org/10.3233/JAD-191197>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

